{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:25:02Z","timestamp":1790115902837,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiovasc Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bone scintigraphy is emerging as a confirmatory diagnostic tool for transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to investigate the frequency and clinical characteristics of patients with incidental cardiac uptake and incidental ATTR-CA on bone scintigraphy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All bone scintigraphic studies performed at a tertiary teaching hospital between 2011 and 2022 were reviewed retrospectively. Patients who underwent bone scintigraphy to confirm ATTR-CA were excluded. Patients with cardiac uptake of grade 2 or 3 were included and divided into two groups: possible ATTR-CA group and noncardiac amyloidosis (non-CA) group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 61,432 bone scintigraphic studies performed on 32,245 patients, 23 (0.07%) had grade 2 or 3 cardiac uptake. Nine of 23 patients (39.1%) were assigned to the non-CA group because they showed cardiac uptake from definite other causes or focal uptake that did not match CA. The remaining 14 patients (60.9%) were classified as the possible ATTR-CA group, and five patients were referred to cardiologists and finally diagnosed with ATTR-CA. Two patients were treated with tafamidis. Patients in the ATTR-CA group were significantly older and had a less frequent history of end-stage renal disease than those in the non-CA group. Other characteristics were comparable in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although incidental ATTR-CA in patients undergoing bone scintigraphy for noncardiac reasons is uncommon, if cardiac uptake is observed in elderly patients without metastatic calcification associated with end-stage renal disease, further diagnostic work-up for ATTR-CA as a cause of undiagnosed heart failure should be considered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s44348-024-00030-5","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:02:04Z","timestamp":1722643324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and characteristics of patients with incidental cardiac uptake on bone scintigraphy"],"prefix":"10.1186","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-0952","authenticated-orcid":false,"given":"Jihee","family":"Son","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-2699","authenticated-orcid":false,"given":"Yeon-Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9752-9717","authenticated-orcid":false,"given":"Sun Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"30_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ehf2.12518","volume":"6","author":"H Yamamoto","year":"2019","unstructured":"Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6:1128\u201339.","journal-title":"ESC Heart Fail"},{"key":"30_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512\u201326.","journal-title":"Eur J Heart Fail"},{"key":"30_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16\u201326.","journal-title":"Circulation"},{"key":"30_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","volume":"9","author":"AS Hafeez","year":"2020","unstructured":"Hafeez AS, Bavry AA. Diagnosis of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2020;9:85\u201395.","journal-title":"Cardiol Ther"},{"key":"30_CR5","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075.","journal-title":"Circ Heart Fail"},{"key":"30_CR6","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7-22.","journal-title":"Circulation"},{"key":"30_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","volume":"7","author":"S Longhi","year":"2014","unstructured":"Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531\u20132.","journal-title":"JACC Cardiovasc Imaging"},{"key":"30_CR8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312.","journal-title":"Circulation"},{"key":"30_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"30_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","volume":"270","author":"L Mohamed-Salem","year":"2018","unstructured":"Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hern\u00e1ndez-Vicente \u00c1, Reyes-Marle R, Castell\u00f3n S\u00e1nchez MI, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018;270:192\u20136.","journal-title":"Int J Cardiol"},{"key":"30_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12350-021-02575-0","volume":"28","author":"M Bianco","year":"2021","unstructured":"Bianco M, Parente A, Biol\u00e8 C, Righetti C, Spirito A, Luciano A, et al. The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy. J Nucl Cardiol. 2021;28:825\u201330.","journal-title":"J Nucl Cardiol"},{"key":"30_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1536\/ihj.18-345","volume":"60","author":"HM Kim","year":"2019","unstructured":"Kim HM, Sohn DW, Paeng JC. Prevalence of positive 99 mTc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly. Int Heart J. 2019;60:643\u20137.","journal-title":"Int Heart J"},{"key":"30_CR13","first-page":"1289","volume":"19","author":"P de Graaf","year":"1978","unstructured":"de Graaf P, Schicht IM, Pauwels EK, te Velde J, de Graeff J. Bone scintigraphy in renal osteodystrophy. J Nucl Med. 1978;19:1289\u201396.","journal-title":"J Nucl Med"},{"key":"30_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.crad.2022.12.004","volume":"78","author":"R Anand Kumar","year":"2023","unstructured":"Anand Kumar R, Maran T, Davidson J, Hassan I. Nuclear medicine imaging findings in end-stage renal disease and renal transplant complications. Clin Radiol. 2023;78:333\u20139.","journal-title":"Clin Radiol"},{"key":"30_CR15","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.14312","volume":"10","author":"O Itzhaki Ben Zadok","year":"2023","unstructured":"Itzhaki Ben Zadok O, Ruhrman-Sahar N, Mats I, Vaxman I, Shiyovich A, Aviv Y, et al. The short and long-term characteristics and outcomes of patients with grade 1 myocardial uptake on cardiac scintigraphy. ESC Heart Fail. 2023;10:1666\u201376.","journal-title":"ESC Heart Fail"},{"key":"30_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","volume":"79","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:1288\u2013303.","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-024-00030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44348-024-00030-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-024-00030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:03:27Z","timestamp":1722643407000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcvi.biomedcentral.com\/articles\/10.1186\/s44348-024-00030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1186\/s44348-024-00030-5","relation":{},"ISSN":["2586-7296"],"issn-type":[{"value":"2586-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"11 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Jeonbuk National University Hospital (No. 2024-02-019). Written informed consent was waived due to the retrospective nature of the study. The analysis was done using anonymous clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}